Retatrutide
Overview
Research-use triple incretin and glucagon receptor agonist supplied for studies of integrated metabolic signaling and energy-balance pathway models.
- Concentration
- 10 mg / 20 mg / 40 mg
- Stock
- Out of stock
Product details
Retatrutide is a synthetic peptide designed for GLP-1, GIP, and glucagon receptor research models of integrated metabolic signaling. Pattern lists this material for controlled laboratory research.
Research Targets: GLP-1 receptor, GIP receptor, glucagon receptor, downstream metabolic signaling networks.
Key Feature: Triple receptor agonist research peptide for multi-hormone pathway studies.
Research Focus Areas: Incretin and glucagon signaling, glucose-regulation pathway models, energy-expenditure models, hepatic metabolic signaling.
Common Models: Receptor assays, rodent metabolic models, liver and adipose signaling systems.
Mechanistic Interests: Multi-receptor activation, insulin and glucagon signaling markers, cAMP pathway dynamics, energy-balance pathway crosstalk.
Use Boundary: Research use only; not for human or veterinary use; no diagnostic, therapeutic, or consumption use is implied.
Product documentation
Certificate of Analysis
Retatrutide
Review the public certificate available for this product before creating an account or checking out.
Research context
Peptide guide
Open full guide- Guide profile
- Triple GIP/GLP-1/Glucagon Agonist
- Composition
- Investigational synthetic peptide and first-in-class triple agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors simultaneously
- Discovery
- Developed by Eli Lilly as LY3437943, extending dual incretin-agonist research by adding glucagon receptor activation to test broader metabolic effects
- Research scope
- Phase 2 trials reported large weight reductions and metabolic-marker changes, while confirmatory Phase 3 evidence is still needed for approved-use framing
- Regulatory status
- Not FDA-approved; investigational pending Phase 3 publication and regulatory review
Safety context
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Hypersensitivity to retatrutide or components
Research-use notice: Retatrutide is an investigational triple-agonist peptide with Phase 2 evidence showing large weight reductions and metabolic effects. It is not FDA-approved as of May 2026, and peer-reviewed Phase 3 efficacy publications, long-term safety data, and cardiovascular outcomes evidence remain pending. Compounded or research-market products lack approved-drug oversight and may vary in quality. Retatrutide's glucagon component introduces unique considerations such as heart-rate changes, so clinical decisions require qualified medical oversight and individualized risk review.
Full guide includes 10 reference entries.
